FINANCIAL STATEMENTS Notes to the financial statements continued 13. Dividend million 2016 2015 Amounts recognised as distributions to equity holders in the year: final dividend for the year ended 31 December 2015 of 2.4 pence per share 2015: 1.8 pence 9.6 7.2 interim dividend for the year ended 31 December 2016 of 1.3 pence per share 2015: 1.3 pence 5.2 5.2 Total 14.8 12.4 A final dividend of 2.5 pence per share, amounting to a total final dividend of approximately 10.1 million, is to be proposed at the Companys annual general meeting on 26 May 2017.
In accordance with IAS 10 Events After the Balance Sheet Date, dividend declared after the balance sheet date is not recognised as a liability in these financial statements.
Earnings per share Basic earnings per share is calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of ordinary shares outstanding during the year.
2016 2015 Profit for the year attributable to owners of the Parent million 53.6 60.0 Weighted average number of ordinary shares 401,081,391 401,081,391 Adjustment for weighted average number of shares held in the EBT 1,085,956 1,195,844 Weighted average number of ordinary shares in issue No.
399,995,435 399,885,547 Basic earnings per share in pence per share 13.4 15.0 For dilutive earnings per share, the weighted average number of ordinary shares in issue is adjusted to include all dilutive potential ordinary shares arising from share options.
2016 2015 Profit for the year attributable to owners of the Parent million 53.6 60.0 Weighted average number of ordinary shares in issue 399,995,435 399,885,547 Adjustment for weighted average number of contingently issuable shares 1,576,430 2,052,534 Diluted weighted average number of ordinary shares in issue No.
Intangible assets million Goodwill Cost: At 1 January 2016 520.1 Written-off 1.3 At 31 December 2016 518.8 Impairment: At 1 January 2016 and 31 December 2016 1.0 Net book value: At 31 December 2016 517.8 At 31 December 2015 519.1 The goodwill arising on acquisitions is reviewed annually for impairment or when there is an event that may indicate impairment.
In the year, the Groups goodwill in relation to the Lifescan business was written-off following a strategic review and the closure of the operation.
The Directors do not believe that any further impairment is required in the current financial year.
Impairment testing The Directors treat the business as a single cash-generating unit for the purposes of testing goodwill for impairment.
The recoverable amount of goodwill is calculated by reference to its estimated value-in-use.
In order to estimate the value-in-use, management has used trading projections covering the three-year period to December 2019, which were extended to cover the five-year period to December 2021.
118 Spire Healthcare Group plc Annual Report 2016
